South Korea’s GC Biopharma Corp. said on Thursday it acquired the US-based medical-grade source blood plasma company ABO Holding Inc.
The size of the purchase was $96 million.
ABO Holding operates six blood centers in California, New Jersey, and Utah. Two more facilities are under construction in Texas, scheduled for completion in 2026.
GC Biopharma plans to diversify the source of raw materials for its immunoglobulin blood product Alyglo (intravenous immunoglobulin 10%).
Alyglo is the treatment for primary humoral immunodeficiency. GC Biopharma received approval from the US Food and Drug Administration (FDA) last year.
Write to Young-Ae Lee at 0ae@hankyung.com
GC Biopharma’s Alyglo production line at its Ochang plant in South Korea (Courtesy of GC Biopharma) CHEONGJU, North Chungcheong Province -- South Korea’s major pharmaceutical company GC Biopharma Corp. aims to raise the sales of Alyglo, its immunoglobulin blood product approved by t